• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

口服葡萄糖耐量试验作为空腹血糖筛查 2 型糖尿病的补充:瑞典韦斯特博滕 14.6 万次健康检查的基于人群的横断面分析。

Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden.

机构信息

Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden.

Department of Public Health and Clinical Medicine, Medicine, Umeå University, Umeå, Sweden.

出版信息

BMJ Open. 2022 Jun 8;12(6):e062172. doi: 10.1136/bmjopen-2022-062172.

DOI:10.1136/bmjopen-2022-062172
PMID:35676014
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9185658/
Abstract

OBJECTIVE

To assess the effect of adding an oral glucose tolerance test (OGTT) to fasting plasma glucose (FPG) in terms of detection of type 2 diabetes (T2D) and impaired glucose tolerance (IGT).

DESIGN

Retrospective analysis of serial cross-sectional screening study.

SETTING

Population-based health examinations within primary care in Västerbotten County, Sweden.

PARTICIPANTS

Individuals aged 40- 50 and 60 years with participation from 1985 to 2017. Those with previously diagnosed diabetes and FPG≥7 mmol/L were excluded.

PRIMARY AND SECONDARY OUTCOME MEASURES

Prevalence of hyperglycaemia on the OGTT (IGT and T2D defined as 2-hour postload capillary plasma glucose of 8.9-12.1 mmol/L and ≥12.2 mmol/L, respectively). Analyses were further stratified by age, sex and risk factor burden to identify groups at high or low risk of IGT and T2D on testing. The numbers needed to screen (NNS) to prevent one case of T2D through detection and treatment of IGT was estimated, combining prevalence numbers with average progression rates and intervention effects from previous meta-analyses.

RESULTS

The prevalence of IGT ranged from 0.9% (95% CI 0.7% to 1.1%) to 29.6% (95% CI 27.4% to 31.7%), and the prevalence of T2D ranged from 0.06% (95% CI 0.02% to 0.11%) to 7.0% (95% CI 5.9% to 8.3%), depending strongly on age, sex and risk factor burden. The estimated NNS to prevent one case of T2D through detection and lifestyle treatment of IGT ranged from 1332 among 40-year-old men without risk factors, to 39 among 60-year-old women with all risk factors combined.

CONCLUSIONS

The prevalence of hyperglycaemia on OGTT is highly dependent on age, sex and risk factor burden; OGTT should be applied selectively to high-risk groups to avoid unnecessary testing in the general population.

摘要

目的

评估口服葡萄糖耐量试验(OGTT)联合空腹血糖(FPG)检测对 2 型糖尿病(T2D)和糖耐量受损(IGT)的影响。

设计

基于人群的初级保健中连续横断面筛查研究的回顾性分析。

地点

瑞典韦斯特博滕县。

参与者

年龄在 40-50 岁和 60 岁之间的个体,1985 年至 2017 年参与其中。已诊断患有糖尿病和 FPG≥7mmol/L 的个体被排除在外。

主要和次要观察指标

OGTT 后高血糖的患病率(IGT 和 T2D 定义为 2 小时毛细血管血浆葡萄糖 8.9-12.1mmol/L 和≥12.2mmol/L)。进一步按年龄、性别和危险因素负担进行分层分析,以确定在检测时处于 IGT 和 T2D 高风险或低风险的人群。根据以前的荟萃分析中患病率数据与平均进展率和干预效果相结合,估计通过检测和治疗 IGT 来预防一例 T2D 所需的筛查人数(NNS)。

结果

IGT 的患病率从 0.9%(95%CI0.7%至 1.1%)到 29.6%(95%CI27.4%至 31.7%)不等,T2D 的患病率从 0.06%(95%CI0.02%至 0.11%)到 7.0%(95%CI5.9%至 8.3%)不等,这强烈取决于年龄、性别和危险因素负担。通过检测和生活方式治疗 IGT 预防一例 T2D 所需的估计 NNS 从无危险因素的 40 岁男性中的 1332 例到所有危险因素合并的 60 岁女性中的 39 例不等。

结论

OGTT 后高血糖的患病率高度依赖于年龄、性别和危险因素负担;OGTT 应选择性地应用于高危人群,以避免在一般人群中进行不必要的检测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f39/9185658/9bbb2d5a3377/bmjopen-2022-062172f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f39/9185658/9bbb2d5a3377/bmjopen-2022-062172f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f39/9185658/9bbb2d5a3377/bmjopen-2022-062172f01.jpg

相似文献

1
Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, Sweden.口服葡萄糖耐量试验作为空腹血糖筛查 2 型糖尿病的补充:瑞典韦斯特博滕 14.6 万次健康检查的基于人群的横断面分析。
BMJ Open. 2022 Jun 8;12(6):e062172. doi: 10.1136/bmjopen-2022-062172.
2
International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes.国际糖尿病联合会关于 1 小时负荷后血浆葡萄糖诊断中间高血糖和 2 型糖尿病的立场声明。
Diabetes Res Clin Pract. 2024 Mar;209:111589. doi: 10.1016/j.diabres.2024.111589. Epub 2024 Mar 7.
3
Impaired glucose regulation in adults in Jamaica: who should have the oral glucose tolerance test?牙买加成年人的血糖调节受损:谁应该进行口服葡萄糖耐量试验?
Rev Panam Salud Publica. 2004 Jul;16(1):35-42. doi: 10.1590/s1020-49892004000700005.
4
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.糖尿病分类与诊断标准委员会报告。
Diabetes Res Clin Pract. 2002 Jan;55(1):65-85. doi: 10.1016/s0168-8227(01)00365-5.
5
Metabolic predictors of impaired glucose tolerance and type 2 diabetes in a predisposed population--A prospective cohort study.易患人群中糖耐量受损和2型糖尿病的代谢预测因素——一项前瞻性队列研究。
BMC Endocr Disord. 2015 Sep 25;15:51. doi: 10.1186/s12902-015-0048-8.
6
Intermediate hyperglycaemia to predict progression to type 2 diabetes (ELSA-Brasil): an occupational cohort study in Brazil.中间高血糖预测 2 型糖尿病的进展(ELSA-Brasil):巴西的一项职业队列研究。
Lancet Diabetes Endocrinol. 2019 Apr;7(4):267-277. doi: 10.1016/S2213-8587(19)30058-0. Epub 2019 Feb 22.
7
[Prevalence of type II diabetes mellitus in population of Krakow].[克拉科夫人群中2型糖尿病的患病率]
Pol Arch Med Wewn. 2001 Sep;106(3):771-9.
8
Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study.使用糖尿病风险评分对未诊断的糖尿病和糖耐量受损进行机会性筛查:IGLOO(糖耐量受损与长期结局观察)研究
Diabetes Care. 2005 May;28(5):1187-94. doi: 10.2337/diacare.28.5.1187.
9
Fasting plasma glucose is not sufficient to detect ongoing glucose intolerance after pregnancy complicated by gestational diabetes.空腹血糖不足以检测妊娠合并妊娠期糖尿病后持续存在的糖耐量异常。
Exp Clin Endocrinol Diabetes. 2010 Apr;118(4):234-6. doi: 10.1055/s-0029-1241876. Epub 2010 Feb 16.
10
A screening procedure detecting high-yield candidates for OGTT. The Women's Health in the Lund Area (WHILA) study: a population based study of middle-aged Swedish women.一种用于检测口服葡萄糖耐量试验(OGTT)高收益候选者的筛查程序。隆德地区妇女健康(WHILA)研究:一项基于瑞典中年女性人群的研究。
Eur J Epidemiol. 2001;17(10):943-51. doi: 10.1023/a:1016291426124.

引用本文的文献

1
Low carbohydrate high fat-diet in real life; A descriptive analysis of cardiovascular risk factors.现实生活中的低碳水化合物高脂肪饮食;心血管危险因素的描述性分析。
Int J Cardiol Cardiovasc Risk Prev. 2025 Mar 8;25:200384. doi: 10.1016/j.ijcrp.2025.200384. eCollection 2025 Jun.
2
A Critical Review of Diagnostic Strategies and Maternal Offspring Complications in Gestational Diabetes Mellitus.妊娠期糖尿病诊断策略与母儿并发症的批判性综述
Cureus. 2023 Dec 24;15(12):e51016. doi: 10.7759/cureus.51016. eCollection 2023 Dec.

本文引用的文献

1
Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement.筛查糖尿病前期和 2 型糖尿病:美国预防服务工作组推荐声明。
JAMA. 2021 Aug 24;326(8):736-743. doi: 10.1001/jama.2021.12531.
2
Cardiovascular risk prediction in type 2 diabetes before and after widespread screening: a derivation and validation study.2 型糖尿病广泛筛查前后的心血管风险预测:一项推导和验证研究。
Lancet. 2021 Jun 12;397(10291):2264-2274. doi: 10.1016/S0140-6736(21)00572-9. Epub 2021 Jun 2.
3
Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
204 个国家和地区 1990-2019 年 87 种风险因素的全球负担:2019 年全球疾病负担研究的系统分析。
Lancet. 2020 Oct 17;396(10258):1223-1249. doi: 10.1016/S0140-6736(20)30752-2.
4
Screening for type 2 diabetes mellitus.2型糖尿病筛查
Cochrane Database Syst Rev. 2020 May 29;5(5):CD005266. doi: 10.1002/14651858.CD005266.pub2.
5
2. Classification and Diagnosis of Diabetes: .2. 糖尿病的分类和诊断: 。
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002.
6
Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study.生活方式干预对糖耐量受损人群的发病率和死亡率的影响:大庆糖尿病预防结局研究 30 年的结果。
Lancet Diabetes Endocrinol. 2019 Jun;7(6):452-461. doi: 10.1016/S2213-8587(19)30093-2. Epub 2019 Apr 26.
7
Diabetes Prevalence Survey of Pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: a population-based survey from Pakistan.巴基斯坦糖尿病患病率调查(DPS-PAK):使用糖化血红蛋白诊断 2 型糖尿病和糖尿病前期的患病率:来自巴基斯坦的一项基于人群的调查。
BMJ Open. 2019 Feb 21;9(2):e025300. doi: 10.1136/bmjopen-2018-025300.
8
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.血糖中度升高人群中2型糖尿病的发生
Cochrane Database Syst Rev. 2018 Oct 29;10(10):CD012661. doi: 10.1002/14651858.CD012661.pub2.
9
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.2 型糖尿病患者的风险因素、死亡率和心血管结局。
N Engl J Med. 2018 Aug 16;379(7):633-644. doi: 10.1056/NEJMoa1800256.
10
Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analysis of screening tests and interventions.筛查和治疗策略在预防 2 型糖尿病中的效果和有效性:筛查试验和干预措施的系统评价和荟萃分析。
BMJ. 2017 Jan 4;356:i6538. doi: 10.1136/bmj.i6538.